Obesity may be a thing of the past if the new injectable weight loss drug has its say. The FDA has just approved the marketing of the anti-obesity drug for public use. Losing weight won’t be any trouble at all. What’s more, Saxenda (liraglutide), that’s the drug’s name, will also take care of health conditions which are related to obesity such as hypertension and type 2 diabetes.
“Obestiy is a public health concern and threatens the overall well-being of patients,” reprots Dr. James Smith, the acting deputy director for the division of metabolism and endocrinology products at the US Food and Drug Administration’s Center for Drug Evaluation and Research. He adds, “Saxenda, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides an additional treatment option for chronic weight management for people who are obese or are overweight and have at least one weight-related comorbid condition.”
The drug has to be used in conjunction with a healthy lifestyle in order to be more effective at bringing down long term weight problems. Responsible use of the drug will help set the tone for solving obesity problems. Using the drugs alone won’t be as effective as when combined with a healthy lifestyle.
The pre-approval trial included 4,800 obese patients who underwent three test runs using the drug. The patients lost 4.5 percent of their weight as a group.
Saxenda belongs to a group of drugs classified as glucagon-like peptide-1 (GLP-1) receptor agonists. Staff physician William Troy Donahoo, of the Metabolic-Surgical Weight Management Department, with Kaiser Permanente of Denver, explained that this drug sends a signal to the brain when “you are full, mimicking the hormone that can help users eat less.”
Some of the side effects of Saxenda may include nausea and vomiting, low blood pressure, diminished appetite, and difficult bowel movement. These are common side effects that affect all the drugs in the same line, which may include reduced kidney function and suicidal tendencies.